Pzena Investment Management, Inc. Announces Fourth-Quarter and Full-Year 2017 Earnings Conference Call

NEW YORK, Jan. 24, 2018 (GLOBE NEWSWIRE) — Pzena Investment Management, Inc. (NYSE:PZN) today announced that it will hold a conference call to discuss the Company’s financial results and outlook at 10:00 a.m. ET, Wednesday, February 7, 2018.  The call will be open to the public.
Webcast Instructions: To gain access to the webcast, which will be “listen-only,” go to the Events page in the Investor Relations area of the Company’s website, www.pzena.com.Teleconference Instructions: To gain access to the conference call via telephone, U.S. callers should dial 844-378-6482; Canada callers should dial 855-669-9657; international callers should dial 412-317-5106.  Please reference the Pzena Investment Management call.   Replay: The conference call will be available for replay through February 21, 2018, on the web using the information given above.About Pzena
Pzena Investment Management, LLC, the firm’s operating company, is a value-oriented investment management firm.  Founded in 1995, Pzena Investment Management has built a diverse, global client base.  More firm and stock information is posted at www.pzena.com.
Gary Bachman, 212-355-1600 or bachman@pzena.com.

Benchmark Electronics to Report Fourth Quarter and FY 2017 Results

SCOTTSDALE, Ariz., Jan. 24, 2018 /PRNewswire/ — Benchmark Electronics, Inc. (NYSE: BHE) will announce its fourth quarter and FY 2017 results on Wednesday, February 7, 2018, after the market closes.  The Company will host a conference call to discuss the results later that day at 5:00 p.m. Eastern Time.

The live webcast of the call and accompanying reference materials will be accessible by logging on to the Company’s website at www.bench.com.  A replay of the broadcast will also be available until Wednesday, February 14, on the Company’s website.

For More Information, Please Contact:
Lisa K. Weeks, VP of Strategy & Investor Relations
623-300-7052 or lisa.weeks@bench.com

About Benchmark Electronics, Inc.:  Benchmark Electronics, Inc. provides worldwide integrated electronic manufacturing services (EMS), engineering and design services, and precision machining services to original equipment manufacturers in the following industries: industrial controls, aerospace and defense, telecommunications, computers and related products for business enterprises, medical devices, and test and instrumentation.  Benchmark has facilities in eight countries, and its common shares trade on the New York Stock Exchange under the symbol BHE.

Cision View original content with multimedia:http://www.prnewswire.com/news-releases/benchmark-electronics-to-report-fourth-quarter-and-fy-2017-results-300587932.html

SOURCE Benchmark Electronics, Inc.

Related Links

http://www.bench.com

Cohen & Steers Limited Duration Preferred and Income Fund, Inc. (LDP) Notification of Sources of Distribution Under Section 19(a)

NEW YORK, Jan. 24, 2018 /PRNewswire/ — This press release provides shareholders of Cohen & Steers Limited Duration Preferred and Income Fund, Inc. (NYSE: LDP) (the “Fund”) with information regarding the sources of the distribution to be paid on January 31, 2018 and cumulative distributions paid fiscal year-to-date.

In December 2016, the Fund implemented a managed distribution policy in accordance with exemptive relief issued by the Securities and Exchange Commission. The managed distribution policy seeks to deliver the Fund’s long-term total return potential through regular monthly distributions declared at a fixed rate per common share. The policy gives the Fund greater flexibility to realize long-term capital gains throughout the year and to distribute those gains on a regular monthly basis to shareholders. The Board of Directors of the Fund may amend, terminate or suspend the managed distribution policy at any time, which could have an adverse effect on the market price of the Fund’s shares.

The Fund’s monthly distributions may include long-term capital gains, short-term capital gains, net investment income and/or return of capital for federal income tax purposes. Return of capital includes distributions paid by the Fund in excess of its net investment income and net realized capital gains and such excess is distributed from the Fund’s assets. A return of capital is not taxable; rather, it reduces a shareholder’s tax basis in his or her shares of the Fund. The amount of monthly distributions may vary depending on a number of factors, including changes in portfolio and market conditions.

At the time of each monthly distribution, information will be posted to cohenandsteers.com and mailed to shareholders in a concurrent notice. However, this information may change at the end of the year because the final tax characteristics of the Fund’s distributions cannot be determined with certainty until after the end of the calendar year. Final tax characteristics of all of the Fund’s distributions will be provided on Form 1099-DIV, which is mailed after the close of the calendar year.

The following table sets forth the estimated amounts of the current distribution and the cumulative distributions paid this fiscal year-to-date from the sources indicated. All amounts are expressed per common share.

DISTRIBUTION ESTIMATES

January 2018

YEAR-TO-DATE (YTD)

January 31, 2018*

Source

Per Share Amount

% of Current Distribution

Per Share Amount

% of 2018 Distributions

Net Investment Income

$0.0000

0.00%

$0.0000

0.00%

Net Realized Short-Term Capital Gains

$0.0000

0.00%

$0.0000

0.00%

Net Realized Long-Term Capital Gains

$0.1560

100.00%

$0.1560

100.00%

Return of Capital (or other Capital Source)

$0.0000

0.00%

$0.0000

0.00%

Total Current Distribution

$0.1560

100.00%

$0.1560

100.00%

You should not draw any conclusions about the Fund’s investment performance from the amount of this distribution or from the terms of the Fund’s managed distribution policy. The amounts and sources of distributions reported in this Notice are only estimates, are likely to change over time, and are not being provided for tax reporting purposes. The actual amounts and sources of the amounts for accounting and tax reporting purposes will depend upon the Fund’s investment experience during the remainder of its fiscal year and may be subject to changes based on tax regulations. The amounts and sources of distributions year-to-date may be subject to additional adjustments.

*THE FUND WILL SEND YOU A FORM 1099-DIV FOR THE CALENDAR YEAR THAT WILL TELL YOU HOW TO REPORT THESE DISTRIBUTIONS FOR FEDERAL INCOME TAX PURPOSES

The Fund’s Year-to-date Cumulative Total Return for fiscal year 2017 (January 1, 2017 through December 31, 2017) is set forth below. Shareholders should take note of the relationship between the Year-to-date Cumulative Total Return with the Fund’s Cumulative Distribution Rate for 2018. In addition, the Fund’s Average Annual Total Return for the five-year period ending December 31, 2017 is set forth below. Shareholders should note the relationship between the Average Annual Total Return with the Fund’s Current Annualized Distribution Rate for 2018. The performance and distribution rate information disclosed in the table is based on the Fund’s net asset value per share (NAV). The Fund’s NAV is calculated as the total market value of all the securities and other assets held by the Fund minus the total liabilities, divided by the total number of shares outstanding. While NAV performance may be indicative of the Fund’s investment performance, it does not measure the value of a shareholder’s individual investment in the Fund. The value of a shareholder’s investment in the Fund is determined by the Fund’s market price, which is based on the supply and demand for the Fund’s shares in the open market.

Fund Performance and Distribution Rate Information:

Year-to-date January 1, 2017 to December 31, 2017

Year-to-date Cumulative Total Return1

15.02%

Cumulative Distribution Rate2

0.57%

Five-year period ending December 31, 2017

Average Annual Total Return3

9.83%

Current Annualized Distribution Rate4

6.89%

1.

Year-to-date Cumulative Total Return is the percentage change in the Fund’s NAV over the year-to-date time period including distributions paid and assuming reinvestment of those distributions.

2.

Cumulative Distribution Rate for the Fund’s current fiscal period (January 1, 2018 through January 31, 2018) measured on the dollar value of distributions in the year-to-date period as a percentage of the Fund’s NAV as of
December 31, 2017.

3.

Average Annual Total Return represents the compound average of the Annual NAV Total Returns of the Fund for the five-year period ending December 31, 2017. Annual NAV Total Return is the percentage change in the Fund’s NAV over a year including distributions paid and assuming reinvestment of those distributions.

4.

The Current Annualized Distribution Rate is the current fiscal period’s distribution rate annualized as a percentage of the Fund’s NAV as of December 31, 2017.

Investors should consider the investment objectives, risks, charges and expense of the fund carefully before investing. You can obtain the fund’s most recent periodic reports, when available, and other regulatory filings by contacting your financial advisor or visiting cohenandsteers.com. These reports and other filings can be found on the Securities and Exchange Commission’s EDGAR Database. You should read these reports and other filings carefully before investing.

Shareholders should not use the information provided in preparing their tax returns. Shareholders will receive a Form 1099-DIV for the calendar year indicating how to report Fund distributions for federal income tax purposes.

Website: http://cohenandsteers.com/
Symbol: (NYSE: CNS)

About Cohen & Steers. Cohen & Steers is a global investment manager specializing in liquid real assets, including real estate securities, listed infrastructure, commodities and natural resource equities, as well as preferred securities and other income solutions. Founded in 1986, the firm is headquartered in New York City, with offices in London, Hong Kong, Tokyo and Seattle.

Cision View original content:http://www.prnewswire.com/news-releases/cohen–steers-limited-duration-preferred-and-income-fund-inc-ldp-notification-of-sources-of-distribution-under-section-19a-300587931.html

SOURCE Cohen & Steers

Related Links

http://www.cohenandsteers.com

Starwood Property Trust Upsizes and Prices Private Offering of Unsecured Senior Notes

GREENWICH, Conn., Jan. 24, 2018 /PRNewswire/ — Starwood Property Trust, Inc. (NYSE: STWD) (the “Company”) today announced that it has upsized and priced its private offering of $500 million aggregate principal amount of its 3.625% unsecured senior notes due February 2021 (the “Notes”). The offering was upsized from the previously announced $400 million aggregate principal amount. The Notes priced at 100.000% of the principal amount and the settlement of the offering is expected to occur on January 29, 2018, subject to customary closing conditions.

The Company intends to use the net proceeds from the offering to pay the cash amounts due on its outstanding 4.55% Convertible Senior Notes due 2018 at maturity or upon conversion, and to use the remaining net proceeds to repay a portion of the amount outstanding under its existing repurchase agreements. The Convertible Senior Notes due 2018 mature on March 1, 2018, and, as of September 30, 2017, approximately $370 million aggregate principal amount of the Convertible Senior Notes due 2018 was outstanding. Amounts that the Company may repay under its revolving repurchase facilities may be re‑borrowed, subject to customary conditions.

The Notes were offered only to qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), and non-U.S. persons pursuant to Regulation S under the Securities Act. The Notes will not initially be registered under the Securities Act or any state securities laws and may not be offered or sold in the United States absent an effective registration statement or an applicable exemption from the registration requirements of the Securities Act or any state securities laws.

This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Starwood Property Trust, Inc.

Starwood Property Trust, Inc. (NYSE: STWD), an affiliate of global private investment firm Starwood Capital Group, is the largest commercial mortgage real estate investment trust in the United States. The Company’s core business focuses on originating, acquiring, financing and managing commercial mortgage loans and other commercial real estate debt and equity investments. Through its subsidiary LNR Property, LLC, the Company also operates as the largest commercial mortgage special servicer in the United States.

Forward-Looking Statements

Statements in this press release which are not historical fact may be deemed forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements with respect to the anticipated settlement of the offering and the use of proceeds. Although the Company believes the expectations reflected in any forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained.  Factors that could cause actual results to differ materially from the Company’s expectations include: (i) factors described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016 and its Quarterly Report on Form 10-Q for the quarter ended September 30, 2017, including those set forth under the captions “Risk Factors” and “Business”; (ii) defaults by borrowers in paying debt service on outstanding indebtedness; (iii) impairment in the value of real estate property securing the Company’s loans or in which the Company invests; (iv) availability of mortgage origination and acquisition opportunities acceptable to the Company; (v) potential mismatches in the timing of asset repayments and the maturity of the associated financing agreements; (vi) national and local economic and business conditions; (vii) general and local commercial and residential real estate property conditions; (viii) changes in federal government policies; (ix) changes in federal, state and local governmental laws and regulations; (x) increased competition from entities engaged in mortgage lending and securities investing activities; (xi) changes in interest rates; and (xii) the availability of, and costs associated with, sources of liquidity.

Contact:

Zachary Tanenbaum
Starwood Property Trust
Phone: 203-422-7788
Email: ztanenbaum@starwood.com

Cision View original content:http://www.prnewswire.com/news-releases/starwood-property-trust-upsizes-and-prices-private-offering-of-unsecured-senior-notes-300587934.html

SOURCE Starwood Property Trust, Inc.

Gates Industrial Corporation plc Announces Pricing of Initial Public Offering

DENVER, Jan. 24, 2018­ /PRNewswire/ — Gates Industrial Corporation plc (“Gates” or “the Company”) (NYSE: GTES), a global manufacturer of products used in many sectors of the industrial and consumer markets, announced today the pricing of its initial public offering of 38,500,000 of its ordinary shares at a price to the public of $19.00 per share.  Gates has granted the underwriters a 30-day option to purchase up to an additional 5,775,000 ordinary shares.  The ordinary shares are expected to begin trading on the New York Stock Exchange on January 25, 2018 under the symbol “GTES.” The offering is expected to close on January 29, 2018, subject to customary closing conditions.

Gates intends to use the net proceeds from the offering primarily to, among other things, repay certain outstanding indebtedness.

Citigroup, Morgan Stanley and UBS Investment Bank are acting as joint book-running managers for the offering. Barclays, Credit Suisse, Goldman Sachs & Co. LLC and RBC Capital Markets are also acting as joint bookrunners for the offering. Blackstone Capital Markets, Deutsche Bank Securities, Wells Fargo Securities, Current Capital Securities LLC, KeyBanc Capital Markets, Siebert Cisneros Shank & Co., L.L.C., SunTrust Robinson Humphrey, Academy Securities, BTIG and Guggenheim Securities are acting as co-managers for the offering.

The offering of these securities is being made only by means of a prospectus. When available, copies of the prospectus relating to the initial public offering may be obtained from: Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by phone at (800) 831-9146; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, Second Floor, New York, NY 10014; or UBS Securities LLC, Attention: Prospectus Department, 1285 Avenue of the Americas, New York, NY 10019 or by phone at (888) 827-7275.

A registration statement relating to these securities was filed with, and declared effective by, the Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Gates Industrial Corporation plc

Gates is a global manufacturer of innovative, highly engineered power transmission and fluid power solutions. Gates offers a broad portfolio of products to diverse replacement channel customers, and to original equipment (“first-fit”) manufacturers as specified components. Gates participates in many sectors of the industrial and consumer markets. Our products play essential roles in a diverse range of applications across a wide variety of end markets ranging from harsh and hazardous industries such as agriculture, construction, manufacturing and energy, to everyday consumer applications such as printers, power washers, automatic doors and vacuum cleaners and virtually every form of transportation. Our products are sold in 128 countries across our four commercial regions: the Americas; Europe, Middle East & Africa; Greater China; and East Asia & India.

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. In some cases, you can identify these forward-looking statements by the use of words such as “outlook,” “believes,” “expects,” “potential,” “continues,” “may,” “will,” “should,” “could,” “seeks,” “predicts,” “intends,” “trends,” “plans,” “estimates,” “anticipates” or the negative version of these words or other comparable words. These forward-looking statements include any statements regarding the commencement of trading of the Company’s ordinary shares on the New York Stock Exchange. Such forward-looking statements are subject to various risks and uncertainties. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. These factors include but are not limited to those described under “Risk Factors” in the Company’s registration statement relating to the initial public offering. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in the registration statement. We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law.

Contact

Bill Waelke
(303) 744-4887
investorrelations@gates.com

Cision View original content with multimedia:http://www.prnewswire.com/news-releases/gates-industrial-corporation-plc-announces-pricing-of-initial-public-offering-300587936.html

SOURCE Gates Industrial Corporation plc

Theatrical Streaming Platform and Subscription Service Cennarium Adds Marcus Ribeiro to Corporate Board of Advisers

NEW YORK, Jan. 24, 2018 /PRNewswire/ — Cennarium, one of the largest streaming services for theatrical productions, has added senior media executive Marcus Vinicius Ribeiro to its corporate board of advisers to help guide the company’s senior management and board of directors on business development, acquisitions and international operations.

Cennarium has also moved its U.S. headquarters to the Paley Center for Media at 25 West 52nd Street, New York, NY 10019. The arrangement for Cennarium to locate at the Paley Center was coordinated by Ribeiro who is a member of the Paley Media Council.

Ribeiro is the Principal for the Americas of PRISA, one of the world’s leading media groups in the Spanish and Portuguese speaking world, creating, producing and distributing content in the area of education, culture, news and information and entertainment. He is responsible for representing all the institutional, commercial, legal and governmental interests of PRISA in the Americas. He also represents the company in several humanitarian, diversity, human-rights, environmental and corporate social responsibility matters. Before joining PRISA’s senior executive team, Ribeiro was chief operating officer and chief legal and corporate officer of the investment boutique Violy & Company, a strategic investment and advisory firm specializing in mergers and acquisitions with extensive experience in the Ibero-American market.

“Cennarium is poised to be the largest streaming service for the performing arts and I am looking forward to working with its senior management toward that end,” said Ribeiro. “Streaming has changed the face of the media business and the way audiences consume content. Cennarium is leading this evolution in the performing arts arena which has until now not had a viable platform and revenue model for distributing its content globally through streaming.”

Cennarium America Inc. is a producer, licensor and online platform for theatrical content, offering subscribers a wide selection of performances from around the world in high-definition encompassing a variety of genres including drama, dance, comedy, music and opera. The company is headquartered in New York and has offices in France and Brazil. More information is available at Cennarium.com and on social media (Twitter: @cennarium, Instagram: @CennariumUSA, Facebook: CennariumUSA).

Contact: Steve Honig, The Honig Company, LLC, 8180-986-4300, press@honigllc.com

Related Links

Cennarium

SOURCE Cennarium Americas Inc.

GW Pharmaceuticals publica un estudio de referencia sobre Epidiolex® en The Lancet

LONDRES y CARLSBAD, California, January 24, 2018 /PRNewswire/ —

– GW Pharmaceuticals y su filial estadounidense Greenwich Biosciences anuncian la publicación del estudio de referencia sobre Epidiolex® (cannabidiol) en The Lancet 

 Primer estudio clínico bien controlado de cannabidiol en el síndrome Lennox-Gastaut, una forma rara y grave de epilepsia de aparición en la infancia que es difícil de tratar –     

 La formulación farmacéutica de cannabidiol redujo significativamente la frecuencia de las caídas violentas por crisis epiléptica (drop attacks) en pacientes con escaso control de las crisis a pesar del uso de varios fármacos antiepilépticos –    

GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “la Compañía” o “el Grupo”), una compañía biofarmacéutica centrada en descubrir, desarrollar y comercializar nuevos medicamentos de su plataforma patentada de productos cannabinoides, junto con su filial estadounidense Greenwich Biosciences, anunció hoy que The Lancet ha publicado resultados de un estudio de Fase 3 de Epidiolex® (cannabidiol) en pacientes con el síndrome de Lennox-Gastaut (LGS).[1] Epidiolex, el producto candidato líder de GW y el primer potencial en una nueva categoría de fármacos antiepilépticos (FAE), es una formulación farmacéutica de cannabidiol purificado (CBD), un cannabinoide que carece de efectos secundarios eufóricos, que está siendo estudiado para el tratamiento de un número de trastornos de epilepsia raros y severos de inicio en la infancia . En este estudio, Epidiolex redujo significativamente la frecuencia mensual de drop attacks en comparación con placebo en pacientes altamente resistentes al tratamiento cuando se añadió al tratamiento existente. El tratamiento con Epidiolex fue generalmente bien tolerado, con un perfil de seguridad consistente con la experiencia divulgada anteriormente.

Una presentación de la Solicitud de Fármaco Nuevo (NDA) a la Administración Estadounidense de Fármacos y Alimentos (FDA) para Epidiolex en el tratamiento de LGS y síndrome de Dravet, (otro tipo de epilepsia rara de inicio en la infancia) fue aceptada en diciembre con una fecha asignada PDUFA del 27 de junio de 2018 y, si se aprueba, la medicina se espera que esté disponible en Estados Unidos para prescripción en la segunda mitad de 2018. Una Solicitud de Autorización de Comercialización (MAA) fue enviada a la Agencia Europea del Medicamento (EMA) en diciembre de 2017, con una decisión prevista para principios de 2019.

“La publicación de este importante estudio en The Lancet es un logro emocionante y marca la segunda vez que los datos de Epidiolex han sido publicados en una revista muy prestigiosa, tras la publicación el año pasado en The New England Journal of Medicine,” dijo Justin Gover, consejero delegado de GW. “Estas publicaciones destacan el potencial de Epidiolex para abordar la importante necesidad de LGS y Síndrome de Dravet, dos condiciones muy desafiantes de epilepsia y esperamos trabajar con la FDA y la EMA para revisar nuestras solicitudes de comercialización para Epidiolex. Estamos absolutamente centrados en el objetivo de hacer este importante potencial tratamiento nuevo disponible para los pacientes y sus cuidadores lo antes posible.”

LGS es una forma rara y permanente de epilepsia que comienza en la infancia y se asocia con una alta tasa de mortalidad[2]  y retrasos importantes en el desarrollo.[3],[4] Los pacientes con LGS sufren de múltiples tipos de crisis, incluyendo drop attacks que pueden originar caídas y otras lesiones. Los resultados de este estudio representan la única evaluación clínica bien controlada de un medicamento cannabinoide para esta condición grave, resistente a los medicamentos.

“La publicación de estos resultados es un hito emocionante para la comunidad de LGS y estamos alentados de que una nueva opción de tratamiento podría estar muy pronto disponible,” dijo Christina SanInocencio, directora ejecutiva de la Lennox-Gastaut Syndrome Foundation. “Opciones de tratamiento adicionales se necesitan desesperadamente para los pacientes que siguen luchando con las crisis incontroladas y estos resultados ofrecen una esperanza muy necesitada a las personas que viven con esta condición debilitante.”

“LGS es uno de los tipos de epilepsia más difíciles de tratar y la mayoría de los pacientes no tienen una respuesta adecuada a las terapias existentes,” dijo Elizabeth Thiele, MD, PhD, directora de epilepsia pediátrica en Massachusetts General Hospital, profesora de Neurología en Harvard Medical School y autora principal del estudio de la publicación. “Estos resultados muestran que Epidiolex puede proporcionar beneficios clínicamente significativos para los pacientes con LGS.”

El estudio aleatorio de 171 pacientes (86 a CBD; 85 a placebo) de entre 2 y 55 años de edad (edad media de 15), con LGS cuyas crisis no fueron controladas por su actual régimen de FAE, recibieron cannabidiol (20mg/kg/día) o placebo además del tratamiento existente. Llevado a cabo en 24 centros de Estados Unidos y Europa, en promedio, los pacientes tomaban aproximadamente tres FAEs, habiendo previamente probado y dejado un promedio de otros seis FAEs. Al inicio del estudio, los pacientes tenían una frecuencia media de 74 drop attacks al mes (drop attacks se definieron como crisisatónica, tónica o tónica-clónica que implican el cuerpo entero, tronco o cabeza que ocasionaron o podrían haber ocasionado  una caída, lesiones, caer sobre una silla o golpearse la cabeza en una superficie).

Durante el período de tratamiento de 14 semanas (periodo de escalado de dosis dos semanas seguido de 12 semanas de mantenimiento), los pacientes que tomaban cannabidiol tuvieron una reducción media significativamente mayor de drop attacks en comparación con placebo (44% vs. 22%; p = 0.0135), el objetivo principal del estudio. Análisis de sensibilidad confirmaron que el efecto del tratamiento de CBD fue establecido durante el primer mes de tratamiento y se mantuvo durante todo el período de tratamiento.

Los resultados de criterios de valoración secundarios clave mostraron que significativamente más pacientes en el grupo de cannabidiol experimentaron una reducción del 50 por ciento o mayor en drop attacks en comparación con placebo (44% vs. 24%; p = 0.0043) y la frecuencia total de las crisis fue significativamente reducida por cannabidiol en comparación con placebo (reducción mediana del porcentaje  de 41% vs. 14%; p = 0.0005). Los pacientes/cuidadores con CBD reportaron de forma significativa   una mejoría en la condición general con cannabidiol comparado conplacebo (58 por ciento vs. 34 por ciento; OR 2.54, 95% CI 1.5-4; p=0.0012) basado en la escala Subject/Caregiver Global Impression of Change (S/CGIC).

Cannabidiol fue generalmente bien tolerado en el ensayo. Los eventos adversos más comunes (EAs) (>10%) fueron diarrea, somnolencia, fiebre, disminución del apetito y vómitos. En general, el 86 por ciento de los pacientes que recibieron Epidiolex y el 69 por ciento de los pacientes que recibieron placebo experimentaron un EA, y la mayoría fueron leves o moderados. De los pacientes que experimentaron EAs, los eventos se resolvieron al final del estudio para el 61 por ciento de los pacientes de cannabidiol y el 64 por ciento de los pacientes con placebo.

Veinte pacientes en cannabidiol experimentaron EAs graves, incluyendo un caso fatal de síndrome de dificultad respiratoria aguda (considerado no relacionado por el investigador), en comparación con los cuatro pacientes con EAs graves con placebo. Doce pacientes en el grupo de cannabidiol interrumpieron el tratamiento debido a EAs en comparación con un paciente en el grupo placebo.

En el programa de desarrollo del cannabidiol, las reacciones adversas más comunes reportadas son somnolencia, disminución del apetito, diarrea, pirexia, fatiga, letargo, erupción, nasofaringitis y neumonía; también se observaron elevación reversible relacionada con la dosis de las transaminasas hepáticas sin elevación de la bilirrubina.

“Las crisis incontroladas impactan de forma significativa en la vida de los pacientes y sus familias y existe una tremenda necesidad de nuevas opciones en epilepsias difíciles de tratar como LGS,” dijo Philip Gattone, presidente y consejero delegado de Epilepsy Foundation. “Este estudio clínico aleatorizado y controlado proporciona una evidencia positiva de la función potencial de cannabidiol en la reducción de las crisis y estamos entusiasmados con la posibilidad de una nueva opción terapéutica para LGS.”

Acerca del síndrome Lennox-Gastaut   

El inicio del LGS típicamente ocurre entre las edades de 3 a 5 años y puede ser causado por una serie de condiciones, incluyendo las malformaciones del cerebro, lesiones graves en la cabeza, infecciones del sistema nervioso central y enfermedades neuro-degenerativas o metabólicas genéticas. En hasta un 30% de los pacientes, no se puede encontrar ninguna causa. Los pacientes con LGS comúnmente tienen múltiples tipos de crisis incluyendo drop attacksy  convulsiones, que con frecuencia conducen a caídas y lesiones, y crisis no convulsivas. La resistencia a los fármacos antiepilépticos (AEDs) es común en pacientes con LGS. La mayoría de los niños con LGS experimenta algún grado de discapacidad intelectual, así como retrasos en el desarrollo y conductas aberrantes.

Acerca del síndrome de Dravet   

El síndrome de Dravet es una encefalopatía epileptica de aparición infantil grave y altamente resistente al tratamiento asociado frecuentemente con una mutación genética en los canales de sodio SCN1A. La aparición del síndrome de Dravet se produce típicamente durante el primer año de vida en bebés previamente sanos y con un desarrollo normal. Las crisis iniciales están a menudo relacionadas con la temperatura, son graves y duraderas. A lo largo del tiempo, las personas con el síndrome de Dravet pueden desarrollar varios tipos de crisis, incluyendo tónico-clónicas, mioclónicas y ausencias atípicas y son propensos a crisis prolongadas incluyendo status epilepticus, el cual  puede ser mortal. El riesgo de muerte prematura, que incluye SUDEP (muerte súbita en epilepsia) es elevado en personas con síndrome de Dravet. Además, la mayoría desarrollará discapacidades de desarrollo e intelectuales de moderadas a graves y requerirá una supervisión y cuidado a lo largo de toda la vida. Actualmente, no hay un tratamiento aprobado por la FDA y casi todos los pacientes siguen teniendo crisis no controladas y otras necesidades médicas a lo largo de su vida.

Acerca de Epidiolex® (cannabidiol)    

Epidiolex, el principal  producto candidato cannabinoide de GW es una formulación farmacéutica de cannabidiol purificado (CBD), que está en desarrollo para el tratamiento de la epilepsia rara y severa, de inicio en la infancia. GW ha presentado una solicitud de nuevo fármaco a la FDA para Epidiolex como tratamiento adyuvante para las crisis asociadas con LGS y el síndrome de Dravet, para la que se ha asignado como fecha objetivo el 27 de junio de 2018 y, de aprobarse, el medicamento estará disponible mediante prescripción en la segunda mitad de 2018. Hasta la fecha, GW ha recibido la designación de fármaco huérfano de la FDA para Epidiolex para el tratamiento del síndrome de Dravet, LGS, TSC e IS. GW ha presentado una Solicitud de Autorización de Marketing (MAA) a la Agencia Europea del Medicamento (EMA) en diciembre de 2017 con una decisión esperada para principios de 2019. Hasta la fecha, GW ha recibido una designación de vía rápida (fast track) de la FDA para el tratamiento del síndrome de Dravet y garantía condicional de designación de enfermedad pediátrica rara por la FDA. La compañía también ha recibido la designación de medicamento huérfano de la Agencia Europea del Medicamento, o EMA, para Epidiolex para el tratamiento de LGS, síndrome de West, síndrome de Dravet y TSC. GW está evaluando programas de desarrollo clínico adicional en otros desórdenes huérfanos incluyendo ensayos de Fase 3 en el complejo de esclerosis tuberosa y espasmos infantiles.

Acerca de GW Pharmaceuticals plc y Greenwich Biosciences    

Fundada en 1998, GW es una compañía biofarmacéutica centrada en descubrir, desarrollar y comercializar nuevas terapias de su plataforma de producto cannabinoide patentada en un amplio rango de enfermedades. GW, junto con su filial estadounidense Greenwich Biosciences, está avanzando en un programa de fármaco huérfano en el campo de la epilepsia de aparición en la infancia con un enfoque en Epidiolex (cannabidiol), para el que GW ha presentado una solicitud de nuevo fármaco a la FDA para el tratamiento adyuvante de LGS y el síndrome de Dravet. La compañía continúa evaluando Epidiolex en otras condiciones epilépticas y actualmente está llevando a cabo ensayos clínicos sobre el complejo de esclerosis tuberosa y los espasmos infantiles. GW comercializó el primer fármaco de prescripción cannabinoide derivado de planta del mundo, Sativex(R) (nabiximols), que está aprobado para el tratamiento de la espasticidad debido a la esclerosis múltiple en 31 países fuera de Estados Unidos. La Compañía tiene una amplia línea de productos candidatos  cannabinoides  que incluye compuestos en ensayos de fase 1 y fase 2 para gliobastoma, esquizofrenia y epilepsia. Para más información, visite http://www.gwpharm.com.

Declaraciones prospectivas  

Este comunicado de prensa contiene declaraciones prospectivas que reflejan las actuales expectativas de GW en cuanto a eventos futuros, incluyendo declaraciones sobre el rendimiento financiero, el plazo de ensayos clínicos o los resultados de decisiones regulatorias y de propiedad intelectual, la relevancia de los productos GW comercialmente disponibles y en desarrollo, los beneficios clínicos de Epidiolex® (cannabidiol) y el perfil de seguridad y potencial comercial de Epidiolex. Las declaraciones prospectivas implican riesgos e incertidumbres. Los eventos reales podrían diferir materialmente de los previstos aquí y dependen de una serie de factores, incluyendo (entre otros), el éxito de las estrategias de investigación de GW, la aplicabilidad de los descubrimientos hechos en ellas, la finalización conéxito y oportuna de incertidumbres asociadas al proceso regulatorio y la aceptación de Sativex, Epidiolex y otros productos por el consumidor y los profesionales médicos. Una lista y descripción de los riesgos e incertidumbres asociados con una inversión en GW puede encontrarse en los documentos de GW presentados a la Comisión de Bolsa y Valores de EE. UU., incluyendo el Formulario 20-F más reciente presentado el 4 de diciembre de 2017. Se insta a los inversores existentes y prospectivos a no depositar una confianza excesiva en estas declaraciones prospectivas, que se refieren solo a la fecha de las mismas. GW no asume ninguna obligación de actualizar o revisar la información contenida en este comunicado, ya sea como resultado de nueva información, eventos futuros o circunstancias de otro tipo.  

Referencias:

  1. Thiele EA, Marsh ED, French JA, et al. Cannabidiol (CBD) Significantly Reduces Drop Seizure Frequency in Lennox-Gastaut Syndrome (LGS): Results of a Multi-center, Randomized, Double-blind, Placebo-controlled Trial (GWPCARE4). Lancet 2017; 376;2011-20.
  2. Autry AR, Trevathan E, Van Naarden Braun K, Yeargin-Allsopp M. Increased risk of death among children with Lennox-Gastaut syndrome and infantile spasms. J Child Neurol. 2010;25(4):441-447.
  3. LGS Foundation. About Lennox-Gastaut Syndrome. Disponible el http://www.lgsfoundation.org/aboutlgs. Consultado el 23 de octubre de 2017.
  4. National Institute of Health. Lennox-Gastaut syndrome. Disponible en https://ghr.nlm.nih.gov/condition/lennox-gastaut-syndrome#definition. Consultado el 23 de octubre de 2017.

Consultas:

GW Pharmaceuticals plc
Stephen Schultz, vicepresidente de relaciones para inversores
(EE. UU.) +1-917-280-2424 / +1-401-500-6570

Consultas para medios de EE. UU.:
Sam Brown Inc. Healthcare
Communications
Christy Curran +1-615-414-8668

Mike Beyer, +1-312-961-2502

Consultas para medios de la UE:
FTI Consulting
Con Franklin, +44(0)7817-573-659

SOURCE GW Pharmaceuticals

Cohen & Steers Select Preferred and Income Fund, Inc. (PSF) Notification of Sources of Distribution Under Section 19(a)

NEW YORK, Jan. 24, 2018 /PRNewswire/ — This press release provides shareholders of Cohen & Steers Select Preferred and Income Fund, Inc. (NYSE: PSF) (the “Fund”) with information regarding the sources of the distribution to be paid on January 31, 2018 and cumulative distributions paid fiscal year-to-date.

In December 2016, the Fund implemented a managed distribution policy in accordance with exemptive relief issued by the Securities and Exchange Commission. The managed distribution policy seeks to deliver the Fund’s long-term total return potential through regular monthly distributions declared at a fixed rate per common share. The policy gives the Fund greater flexibility to realize long-term capital gains throughout the year and to distribute those gains on a regular monthly basis to shareholders. The Board of Directors of the Fund may amend, terminate or suspend the managed distribution policy at any time, which could have an adverse effect on the market price of the Fund’s shares.

The Fund’s monthly distributions may include long-term capital gains, short-term capital gains, net investment income and/or return of capital for federal income tax purposes. Return of capital includes distributions paid by the Fund in excess of its net investment income and net realized capital gains and such excess is distributed from the Fund’s assets. A return of capital is not taxable; rather, it reduces a shareholder’s tax basis in his or her shares of the Fund. The amount of monthly distributions may vary depending on a number of factors, including changes in portfolio and market conditions.

At the time of each monthly distribution, information will be posted to cohenandsteers.com and mailed to shareholders in a concurrent notice. However, this information may change at the end of the year because the final tax characteristics of the Fund’s distributions cannot be determined with certainty until after the end of the calendar year. Final tax characteristics of all of the Fund’s distributions will be provided on Form 1099-DIV, which is mailed after the close of the calendar year.

The following table sets forth the estimated amounts of the current distribution and the cumulative distributions paid this fiscal year-to-date from the sources indicated. All amounts are expressed per common share.

DISTRIBUTION ESTIMATES

January 2018

YEAR-TO-DATE (YTD)

January 31, 2018*

Source

Per Share
Amount

% of Current
Distribution

Per Share
Amount

% of 2018
Distributions

Net Investment Income

$0.0000

0.00%

$0.0000

0.00%

Net Realized Short-Term Capital Gains

$0.0000

0.00%

$0.0000

0.00%

Net Realized Long-Term Capital Gains

$0.1720

100.00%

$0.1720

100.00%

Return of Capital (or other Capital Source)

$0.0000

0.00%

$0.0000

0.00%

Total Current Distribution

$0.1720

100.00%

$0.1720

100.00%

You should not draw any conclusions about the Fund’s investment performance from the amount of this distribution or from the terms of the Fund’s managed distribution policy. The amounts and sources of distributions reported in this Notice are only estimates, are likely to change over time, and are not being provided for tax reporting purposes. The actual amounts and sources of the amounts for accounting and tax reporting purposes will depend upon the Fund’s investment experience during the remainder of its fiscal year and may be subject to changes based on tax regulations. The amounts and sources of distributions year-to-date may be subject to additional adjustments.

*THE FUND WILL SEND YOU A FORM 1099-DIV FOR THE CALENDAR YEAR THAT WILL TELL YOU HOW TO REPORT THESE DISTRIBUTIONS FOR FEDERAL INCOME TAX PURPOSES

The Fund’s Year-to-date Cumulative Total Return for fiscal year 2017 (January 1, 2017 through December 31, 2017) is set forth below. Shareholders should take note of the relationship between the Year-to-date Cumulative Total Return with the Fund’s Cumulative Distribution Rate for 2018. In addition, the Fund’s Average Annual Total Return for the five-year period ending December 31, 2017 is set forth below. Shareholders should note the relationship between the Average Annual Total Return with the Fund’s Current Annualized Distribution Rate for 2018. The performance and distribution rate information disclosed in the table is based on the Fund’s net asset value per share (NAV). The Fund’s NAV is calculated as the total market value of all the securities and other assets held by the Fund minus the total liabilities, divided by the total number of shares outstanding. While NAV performance may be indicative of the Fund’s investment performance, it does not measure the value of a shareholder’s individual investment in the Fund. The value of a shareholder’s investment in the Fund is determined by the Fund’s market price, which is based on the supply and demand for the Fund’s shares in the open market.

Fund Performance and Distribution Rate Information:

Year-to-date January 1, 2017 to December 31, 2017

Year-to-date Cumulative Total Return1

15.87%

Cumulative Distribution Rate2

0.62%

Five-year period ending December 31, 2017

Average Annual Total Return3

9.89%

Current Annualized Distribution Rate4

7.43%

1.

Year-to-date Cumulative Total Return is the percentage change in the Fund’s NAV over the year-to-date time period including distributions paid and assuming reinvestment of those distributions.

2.

Cumulative Distribution Rate for the Fund’s current fiscal period (January 1, 2018 through January 31, 2018) measured on the dollar value of distributions in the year-to-date period as a percentage of the Fund’s NAV as of

December 31, 2017.

3.

Average Annual Total Return represents the compound average of the Annual NAV Total Returns of the Fund for the five-year period ending December 31, 2017. Annual NAV Total Return is the percentage change in the Fund’s NAV over a year including distributions paid and assuming reinvestment of those distributions.

4.

The Current Annualized Distribution Rate is the current fiscal period’s distribution rate annualized as a percentage of the Fund’s NAV as of December 31, 2017.

Investors should consider the investment objectives, risks, charges and expense of the fund carefully before investing. You can obtain the fund’s most recent periodic reports, when available, and other regulatory filings by contacting your financial advisor or visiting cohenandsteers.com. These reports and other filings can be found on the Securities and Exchange Commission’s EDGAR Database. You should read these reports and other filings carefully before investing.

Shareholders should not use the information provided in preparing their tax returns. Shareholders will receive a Form 1099-DIV for the calendar year indicating how to report Fund distributions for federal income tax purposes.

Website: http://cohenandsteers.com/  
Symbol: (NYSE: CNS)

About Cohen & Steers. Cohen & Steers is a global investment manager specializing in liquid real assets, including real estate securities, listed infrastructure, commodities and natural resource equities, as well as preferred securities and other income solutions. Founded in 1986, the firm is headquartered in New York City, with offices in London, Hong Kong, Tokyo and Seattle.

Cision View original content:http://www.prnewswire.com/news-releases/cohen–steers-select-preferred-and-income-fund-inc-psf-notification-of-sources-of-distribution-under-section-19a-300587939.html

SOURCE Cohen & Steers

Related Links

http://www.cohenandsteers.com

China's Dalian Fusheng Pharmaceutical Company Co., Ltd. Makes Contribution to Fund Research in Aging and Immunity Sponsored by the Irma and Paul Milstein Program for Senior Health through Milstein Medical Asian American Partnership (MMAAP) Foundatio

NEW YORK, Jan. 24, 2018 /PRNewswire/ — Dalian Fusheng Pharmaceutical Company Co., Ltd, a major pharmaceutical company in Dalian, China has contributed $100,000 to the Milstein Medical Asian American Partnership (MMAAP) Foundation to support research at Johns Hopkins University focusing on aging and immunity. Dr. Li Fu, Chair of Dalian Fusheng Pharmaceutical Company Co., Ltd, signed an MOU with Mr. Howard P. Milstein, Chairman of MMAAP Foundation, to fund work in 2018 sponsored by the MMAAP Foundation’s Irma and Paul Milstein Program for Senior Health, with a commitment to contribute another $100,000 to those research efforts in 2019.

Dalian Fusheng Pharmaceutical Company Co., Ltd specializes in ginsenoside Rg3, botanical extracts and Traditional Chinese Medicine. Focused on innovation, it has extensive experience in producing high quality botanical extracts for dietary supplement, as well as excellent pharmaceutical and nutraceutical products.

The MMAAP Foundation was established in 2011 with a strong endorsement from China’s former Ministry of Health (now the National Health and Family Planning Commission). Its mission is to improve world health by facilitating exchanges and long-term partnerships between leading medical institutions and medical talent from the United States and China, as well as greater Asia. The Foundation currently offers funding opportunities for Chinese researchers in Geriatric Medicine, Dermatology, Hematology, Reproductive Medicine and Translational Medicine in the form of fellowships and research project awards. The MMAAP Foundation plans to support other disciplines of research and make funding available to investigators from other regions of Asia in the future.

Dalian Fusheng Pharmaceutical’s relationship with the MMAAP Foundation began in 2016 when the company contributed $85,000 to support a MMAAP Foundation Fellowship Award in geriatric medicine under the Irma and Paul Milstein Program for Senior Health.

“Mr. Milstein and MMAAP Foundation have funded many Chinese clinical and medical talents’ studies and research. They helped to develop leadership in Chinese medical field, which is exactly what’s in need in today’s China.” said Dr. Fu Li, Chair of Dalian Fusheng Pharmaceutical Company Co., Ltd.

“Enhancing senior health care is crucial for China as well as the rest of the world,” said Howard P. Milstein, Chairman of the MMAAP Foundation. “I am appreciative of Dalian Fusheng Pharmaceutical Company’s support of our mission. Such a generous contribution will not only help us to facilitate important medical progress in an international setting, but also build trust and collaboration that will benefit future generations.”

Dalian Fusheng Pharmaceutical Company Co., Ltd.

Fusheng Pharmaceutical Co., Ltd specializes in ginsenoside Rg3, botanical extracts and Traditional Chinese Medicine. It has extensive experience in producing high quality botanical extracts for dietary supplement, as well as in the pharmaceutical and nutraceutical industries. It is the leading manufacturer of ginsenoside Rg3 in the world. As a science-driven company, it is committed to providing customers with the highest quality products and excellent service.

Milstein Medical Asian American Partnership (MMAAP) Foundation

The mission of the Milstein Medical Asian American Partnership Foundation (MMAAP Foundation) is to improve world health by developing mutually beneficial partnerships between the U.S. and China, as well as greater Asia. Working with some of the premier health organizations in the world, the MMAAP Foundation brings together and funds exchanges between top researchers, medical talent, and medical institutions.

For more than 50 years, the Milstein family has been actively involved in health-related and medical philanthropy, focusing on five areas: Senior Healthcare, Skin Disease and Melanoma, Reproductive Biology, Blood Research, and Translational Medicine. The MMAAP Foundation builds upon this distinguished history, working in close collaboration with other medical organizations supported by the Milstein family, including American Skin Association, the Milstein Melanoma Research Program at the Rockefeller University, the Howard and Georgeanna Jones Foundation for Reproductive Medicine and the Program for Translational Chemical Biology at New York-Presbyterian Hospital/Weill Cornell Medical Center. The MMAAP Foundation is a 501(c) (3) non-profit organization. For more information, please visit the MMAAP Foundation’s website: www.mmaapf.org.  

Cision View original content:http://www.prnewswire.com/news-releases/chinas-dalian-fusheng-pharmaceutical-company-co-ltd-makes-contribution-to-fund-research-in-aging-and-immunity-sponsored-by-the-irma-and-paul-milstein-program-for-senior-health-through-milstein-medical-asian-american-partnershi-300587917.html

SOURCE Milstein Medical Asian American Partnership Foundation

Cohen & Steers Quality Income Realty Fund, Inc. (RQI) Notification of Sources of Distribution Under Section 19(a)

NEW YORK, Jan. 24, 2018 /PRNewswire/ — This press release provides shareholders of Cohen & Steers Quality Income Realty Fund, Inc. (NYSE: RQI) (the “Fund”) with information regarding the sources of the distribution to be paid on January 31, 2018 and cumulative distributions paid fiscal year-to-date.

In December 2012, the Fund implemented a managed distribution policy in accordance with exemptive relief issued by the Securities and Exchange Commission. The managed distribution policy seeks to deliver the Fund’s long-term total return potential through regular monthly distributions declared at a fixed rate per common share. The policy gives the Fund greater flexibility to realize long-term capital gains throughout the year and to distribute those gains on a regular monthly basis to shareholders. The Board of Directors of the Fund may amend, terminate or suspend the managed distribution policy at any time, which could have an adverse effect on the market price of the Fund’s shares. 

The Fund’s monthly distributions may include long-term capital gains, short-term capital gains, net investment income and/or return of capital for federal income tax purposes. Return of capital includes distributions paid by the Fund in excess of its net investment income and net realized capital gains and such excess is distributed from the Fund’s assets. A return of capital is not taxable; rather, it reduces a shareholder’s tax basis in his or her shares of the Fund. In addition, distributions from the Fund’s investments in real estate investment trusts (REITs) may later be characterized as capital gains and/or a return of capital, depending on the character of the dividends reported to the Fund after year end by REITs held by the Fund. The amount of monthly distributions may vary depending on a number of factors, including changes in portfolio and market conditions.

At the time of each monthly distribution, information will be posted to cohenandsteers.com and mailed to shareholders in a concurrent notice. However, this information may change at the end of the year because the final tax characteristics of the Fund’s distributions cannot be determined with certainty until after the end of the calendar year. Final tax characteristics of all of the Fund’s distributions will be provided on Form 1099-DIV, which is mailed after the close of the calendar year.

The following table sets forth the estimated amounts of the current distribution and the cumulative distributions paid this fiscal year-to-date from the sources indicated. All amounts are expressed per common share.

DISTRIBUTION ESTIMATES

January 2018

YEAR-TO-DATE (YTD)

January 31, 2018*

Source

Per Share
Amount

% of Current
Distribution

Per Share
Amount

% of 2018
Distributions

Net Investment Income

$0.0000

0.00%

$0.0000

0.00%

Net Realized Short-Term Capital Gains

$0.0000

0.00%

$0.0000

0.00%

Net Realized Long-Term Capital Gains

$0.0800

100.00%

$0.0800

100.00%

Return of Capital (or other Capital Source)

$0.0000

0.00%

$0.0000

0.00%

Total Current Distribution

$0.0800

100.00%

$0.0800

100.00%

You should not draw any conclusions about the Fund’s investment performance from the amount of this distribution or from the terms of the Fund’s managed distribution policy. The amounts and sources of distributions reported in this Notice are only estimates, are likely to change over time, and are not being provided for tax reporting purposes. The actual amounts and sources of the amounts for accounting and tax reporting purposes will depend upon the Fund’s investment experience during the remainder of its fiscal year and may be subject to changes based on tax regulations. The amounts and sources of distributions year-to-date may be subject to additional adjustments.  

*THE FUND WILL SEND YOU A FORM 1099-DIV FOR THE CALENDAR YEAR THAT WILL TELL YOU HOW TO REPORT THESE DISTRIBUTIONS FOR FEDERAL INCOME TAX PURPOSES.

The Fund’s Year-to-date Cumulative Total Return for fiscal year 2017 (January 1, 2017 through December 31, 2017) is set forth below. Shareholders should take note of the relationship between the Year-to-date Cumulative Total Return with the Fund’s Cumulative Distribution Rate for 2018. In addition, the Fund’s Average Annual Total Return for the five-year period ending December 31, 2017 is set forth below. Shareholders should note the relationship between the Average Annual Total Return with the Fund’s Current Annualized Distribution Rate for 2018. The performance and distribution rate information disclosed in the table is based on the Fund’s net asset value per share (NAV). The Fund’s NAV is calculated as the total market value of all the securities and other assets held by the Fund minus the total liabilities, divided by the total number of shares outstanding. While NAV performance may be indicative of the Fund’s investment performance, it does not measure the value of a shareholder’s individual investment in the Fund. The value of a shareholder’s investment in the Fund is determined by the Fund’s market price, which is based on the supply and demand for the Fund’s shares in the open market.

Fund Performance and Distribution Rate Information:

Year-to-date January 1, 2017 to December 31, 2017

Year-to-date Cumulative Total Return1

9.18%

Cumulative Distribution Rate2

0.59%

Five-year period ending December 31, 2017

Average Annual Total Return3

12.45%

Current Annualized Distribution Rate4

7.06%

1.

Year-to-date Cumulative Total Return is the percentage change in the Fund’s NAV over the year-to-date time period including distributions paid and assuming reinvestment of those distributions.

2.

Cumulative Distribution Rate for the Fund’s current fiscal period (January 1, 2018 through January 31, 2018) measured on the dollar value of distributions in the year-to-date period as a percentage of the Fund’s NAV as of December 31, 2017.

3.

Average Annual Total Return represents the compound average of the Annual NAV Total Returns of the Fund for the five-year period ending December 31, 2017. Annual NAV Total Return is the percentage change in the Fund’s NAV over a year including distributions paid and assuming reinvestment of those distributions.

4.

The Current Annualized Distribution Rate is the current fiscal period’s distribution rate annualized as a percentage of the Fund’s NAV as of December 31, 2017.

Investors should consider the investment objectives, risks, charges and expense of the fund carefully before investing. You can obtain the fund’s most recent periodic reports, when available, and other regulatory filings by contacting your financial advisor or visiting cohenandsteers.com. These reports and other filings can be found on the Securities and Exchange Commission’s EDGAR Database. You should read these reports and other filings carefully before investing.

Shareholders should not use the information provided in preparing their tax returns. Shareholders will receive a Form 1099-DIV for the calendar year indicating how to report Fund distributions for federal income tax purposes.

Website: http://cohenandsteers.com/ 
Symbol: NYSE: CNS

About Cohen & Steers. Cohen & Steers is a global investment manager specializing in liquid real assets, including real estate securities, listed infrastructure, commodities and natural resource equities, as well as preferred securities and other income solutions. Founded in 1986, the firm is headquartered in New York City, with offices in London, Hong Kong, Tokyo and Seattle.

Cision View original content:http://www.prnewswire.com/news-releases/cohen–steers-quality-income-realty-fund-inc-rqi-notification-of-sources-of-distribution-under-section-19a-300587919.html

SOURCE Cohen & Steers

Related Links

http://www.cohenandsteers.com